MediciNova (MNOV) – Analysts’ Weekly Ratings Updates

MediciNova (NASDAQ: MNOV) recently received a number of ratings updates from brokerages and research firms:

• 3/31/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/23/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/15/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 3/14/2025 – MediciNova had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
• 3/7/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/27/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/21/2025 – MediciNova had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
• 2/19/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/11/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/3/2025 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

MediciNova Trading Down 0.7 %

NASDAQ:MNOV traded down $0.01 on Tuesday, hitting $1.45. The company had a trading volume of 5,645 shares, compared to its average volume of 39,823. MediciNova, Inc. has a 52 week low of $1.12 and a 52 week high of $2.55. The stock has a market capitalization of $71.12 million, a price-to-earnings ratio of -6.30 and a beta of 0.73. The firm has a 50 day moving average of $1.72 and a two-hundred day moving average of $1.87.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings data on Wednesday, February 19th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). As a group, equities analysts forecast that MediciNova, Inc. will post -0.24 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MNOV. Jane Street Group LLC acquired a new position in MediciNova in the 3rd quarter valued at approximately $30,000. Millennium Management LLC grew its stake in shares of MediciNova by 26.7% in the fourth quarter. Millennium Management LLC now owns 25,923 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 5,470 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in MediciNova in the fourth quarter valued at $78,000. SBI Securities Co. Ltd. bought a new position in MediciNova during the 4th quarter worth $113,000. Finally, Barclays PLC lifted its holdings in MediciNova by 15.5% during the 4th quarter. Barclays PLC now owns 95,600 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 12,800 shares during the period. Institutional investors and hedge funds own 9.90% of the company’s stock.

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.